CoChat

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies

Open access
Imai, Yoichi, Maru, Yoshiro, Tanaka, Junji · 2016 · Cancer Science
Cited by 63

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Histone deacetylases (HDAC s) critically regulate gene expression by determining the acetylation status of histones. Studies have increasingly focused on the activities of HDAC s, especially involving non‐histone proteins, and their various biological effects. Aberrant HDAC expression observed in several kinds of human tumors makes HDAC s potential targets for cancer treatment. Several preclinical studies have suggested that HDAC inhibitors show some efficacy in the treatment of acute myelogenous leukemia with AML 1‐ETO, which mediates transcriptional repression through its interaction with a complex including HDAC 1. Recurrent mutations in epigenetic regulators are found in T‐cell lymphomas (TCL s), and HDAC inhibitors and hypomethylating agents were shown to act cooperatively in the treatment of TCL s. Preclinical modeling has suggested that persistent activation of the signal transducer and activator of transcription signaling pathway could serve as a useful biomarker of resistance to HDAC inhibitor in patients with cutaneous TCL. Panobinostat, a pan‐HDAC inhibitor, in combination with bortezomib and dexamethasone, has achieved longer progression‐free survival in patients with relapsed/refractory multiple myeloma (MM) than the placebo in combination with bortezomib and dexamethasone. Panobinostat inhibited MM cell growth by degrading protein phosphatase 3 catalytic subunit α (PPP 3 CA), a catalytic subunit of calcineurin. This degradation was suggested to be mediated by the blockade of the chaperone function of heat shock protein 90 due to HDAC 6 inhibition. Aberrant PPP 3 CA expression in advanced MM indicated a possible correlation between high PPP 3 CA expression and the pathogenesis of MM. Furthermore, PPP 3 CA was suggested as a common target of panobinostat and bortezomib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cas.13062

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

Metadata

Authors
Imai, Y., Maru, Y., & Tanaka, J.
Venue
Cancer Science
Publisher
Wiley
Published
2016-11
Volume
107
Issue
11
Pages
1543-1549
ISSN
  • 1347-9032 (ISSN-L)
  • 1349-7006
OpenAlex
W2515357476
Cited by
63
References
8
FWCI
3.61
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.